As of November 6, 2026, Corvus Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: CRVS). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 10.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Richard A. Miller (7.8%), BlackRock (7.5%), Sirenia Capital Management LP (7.5%) (Schedule 13D/A, January 27, 2026).
Is this your company?
About to sign with, pay or invest in Corvus Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Corvus Pharmaceuticals, Inc. a real, registered company?
- Corvus Pharmaceuticals, Inc. files with the SEC under CIK 1626971 (its SEC filings).
- Its shares are listed under the ticker CRVS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CORVUS PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Andrew C. Chan (Form 8-K filed 2026-04-23). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-08-07).
Who are Corvus Pharmaceuticals, Inc.'s owners and officers?
Corvus Pharmaceuticals, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.3% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 7.5% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 7.5% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 0% |
| Schedule 13G/A, 2026-04-27 | Blackrock, Inc. | 6.4% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-13 | Richard A. Miller | 7.8% |
| Schedule 13D/A, 2026-02-05 | Adams Street Partners, LLC | 3.9% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 5.18% |
| Schedule 13D/A, 2026-01-27 | Orbimed Advisors LLC | 10.3% |
| Schedule 13G, 2025-10-17 | Blackrock, Inc. | 5.4% |
| Schedule 13G/A, 2025-08-14 | Samlyn Capital, LLC | 0% |
Questions about who owns Corvus Pharmaceuticals, Inc.
Who owns Corvus Pharmaceuticals, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Corvus Pharmaceuticals, Inc.: Orbimed Advisors LLC (10.3%, Schedule 13D/A, filed 2026-01-27), Richard A. Miller (7.8%, Schedule 13G/A, filed 2026-02-13), Blackrock, Inc. (7.5%, Schedule 13G/A, filed 2026-07-27), Sirenia Capital Management LP (7.5%, Schedule 13G, filed 2026-05-15) and State Street Corporation (5.3%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Corvus Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Corvus Pharmaceuticals, Inc. on this page are Orbimed Advisors LLC (10.3%), Richard A. Miller (7.8%) and Blackrock, Inc. (7.5%).
When did Orbimed Advisors LLC buy into Corvus Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-01-27, reporting 10.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Corvus Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Corvus Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Corvus Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-23 | Andrew C. Chan | appointed | 2026-04-23 |
Which insiders own Corvus Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 8,819,091 shares (10.5% of shares outstanding), 210,000 held directly and 8,609,091 indirectly (Form 4, 2026-01-30).
- OrbiMed, a director and 10% owner: 7,165,006 shares (8.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-07-01).
- OrbiMed Capital GP V LLC, a director and 10% owner: 7,165,006 shares (8.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-07-01).
- , the chief executive and president: 2,331,742 shares (2.8% of shares outstanding), 1,136,707 held directly and 1,195,035 indirectly (Form 4, 2026-05-20).
- Jones William Benton: 173,130 shares (0.21% of shares outstanding) (Form 4, 2025-06-06).
Shares outstanding: 84,353,126 as of 2026-11-05, from the company's latest SEC cover page.
How much has Corvus Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Corvus Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Corvus Pharmaceuticals, Inc. and the records around it.
Corvus Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jul 2026
Companies that share a holder
- SAMLYN CAPITAL, LLC also filed stake reports on 2 other companies: PureCycle Technologies, Inc. (May 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/corvus-pharmaceuticals